http://www.biosquare.com/http://www.biosquare.com/lists/SYSTEM/fi...

http://www.biosquare.com/

http://www.biosquare.com/lists/SYSTEM/files/sponsors.pdf

more on page 388 of the document

Attending Companies Biosquare 2010

TRANSGENE

Company overview

Transgene is a biopharmaceutical company based in Strasbourg, France, that designs and develops therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseasers. Its expertise covers all product development stages, including research, production of clinical batches and conducting clinical trials.
Five products are currently under clinical development, three in phase II and two in phase I.
A partnership agreement has been signed with Roche for the further development of one of these products, TG4001/R3484, for the treatment of precancerous cervical lesions caused by the HPV virus.
The company has a number of exclusive and innovative technologies using viral vectors. Its proprietary gene transfer technology is protected by an extensive portfolio of intellectual property rights.

Partnering objectives
- to seek out partnership opportunities (out-licensing/ co-development) for Transgene's advanced pre-clinical / clinical product candidates, i.e. in HCV area/ and monoclonal antibodies in Oncology;
- to identify opportunities to expand Transgenes product portfolio through in-licensing, acquisition, product (co-)development and (co-)marketing arrangements;
- to search non-exclusive agreements to maximize the value of Transgene technology platform;
Product(s)
Name TG4010 (MVA-MUC1-IL2) - TARGETED ACTIVE IMMUNOTHERAPY
DESIGNED TO TREAT MUC1- EXPRESSING SOLID TUMORS

Description

TG4010 is in development for the treatment of metatstatic non small cell lung cancer (NSCLC), in combination with first line chemotherapy.
TG4010 is based on a recombinant vaccinia virus expressing the MUC1 antigen and the human cytokine, Interleukin-2 (IL2). TG4010 is meant to induce both innate and adaptive immune responses.
The efficacy and safety of TG4010 have been assessed in a randomized, controlled Phase IIb study evaluating TG4010 as an adjunct to standard chemotherapy in 148 patients with advanced NSCLC.
The primary objective of the study was met (Progression free survival at 6 months of at least 40% in the experimental arm).
TG4010 received in December 2009 the FDA Fast Track Status.

Type
Molecule
Therapeutic areas Cancer / Oncology
Development status Phase 2
Partnering opportunity Development